#compounded

8 articles tagged #compounded.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

Editorial still-life evoking metabolic balance and women's health, warm natural light
GuideCost & InsuranceJune 24, 202611 min read

GLP-1 for PCOS (2026): Ozempic, Wegovy & Cheaper Compounded Paths

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

Editorial photograph illustrating the FDA compounded semaglutide enforcement crackdown
NewsCost & InsuranceJune 19, 202613 min read

Compounded Semaglutide Ban (2026): FDA Crackdown Explained + 4 Legal Switch Options

Updated June 29, 2026: FDA issued 30 warning letters to telehealth companies June 15 for illegally marketing compounded GLP-1s. 503B permanent exclusion comment period extended to July 30, 2026 (from June 29 via FR 2026-12937). FDA proposed April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 million patients affected. Legal alternatives: compounded tirzepatide ($149-299/mo, medical-necessity only), Wegovy $349/mo via NovoCare, or Foundayo from $149/mo self-pay.

Editorial lifestyle photograph of official documents on an oak desk illustrating a regulatory proposal
NewsNews & PipelineMay 8, 20267 min read

FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026, Updated June 29, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list, forever, not just during shortage enforcement. Public comment period extended to July 30, 2026 (from June 29 via Federal Register 2026-12937, published June 26, 2026). If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.

Editorial lifestyle photograph accompanying a tirzepatide dosage chart and weight loss schedule guide
GuideGuidesMay 7, 20269 min read

Tirzepatide Dosage Chart for Weight Loss 2026: Complete Schedule (Zepbound, Mounjaro & Compounded)

Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1, equivalent to roughly 47 lbs for a 225-lb person. The 5 mg and 10 mg doses are also valid long-term maintenance doses (15% and 19.5% weight loss respectively). Same dosing schedule applies to Zepbound, Mounjaro, and compounded tirzepatide.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Yucca Health

7.7/10
$146/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

TrimRx

7.8/10
$149/mo·Compounded

SkinnyRx

7.3/10
$199/mo·Compounded

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.